Approved antibody and cell therapies now face ADCs with pivotal results, while bispecifics advance into Phase 3. The map below selects 20 programs across gastric/gastroesophageal junction (GEJ) cancer and other solid-tumor settings, including pancreatic cancer.
Selected programs by modality and stage
Expand a program to see its reviewed status, development context and trial sources.
| Modality | Earlier clinical / Phase 3 pending | Phase 3 underway | Filing / positive Phase 3 readout | Approved in stated market |
|---|---|---|---|---|
| Antibodies | Osemitamab / TST001TranscentaPhase 3 not yet recruitingPhase 3 registered, not yet recruiting; clinical evidence from earlier phases. Enhanced-effector antibody; planned first-line pembrolizumab/chemotherapy study. Registration is not evidence that Phase 3 dosing began. |
ASKB589AskGenePhase 3 follow-upPhase 3 active, not recruiting. First-line CAPOX plus PD-1 inhibitor combination; estimated primary completion Dec 2026. FG-M108FutureGenGastric Phase 3 recruitingGastric Phase 3 recruiting; pancreatic Phase 3 not yet recruiting. Gastric trial selects HER2-negative, PD-L1 CPS<5 disease and compares M108 plus CAPOX with placebo plus CAPOX. Gastric registry last updated Feb 2024. |
— | Zolbetuximab / VYLOYAstellasUS approvedFDA approved; first-line HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer with chemotherapy. Commercial reference; Phase 3 program adding pembrolizumab. |
| Antibody–drug conjugates | ATG-022AntengenePhase 3 not yet recruitingPhase 3 registered, not yet recruiting. MMAE ADC; Phase 3 listing updated 31 Aug 2026. Clinical Phase 1/2 program exists. ASP546C / XNW27011Astellas / EvopointPhase 1/2 recruitingPhase 1/2 recruiting. TOP1 ADC; ex-Greater-China rights licensed to Astellas. RC118RemeGenPhase 1/2 registry listingPhase 1/2 recruiting in registry; updates dated Jan 2025. MMAE ADC; earlier clinical watchlist, with aged registry timelines. SKB315KelunPhase 1; Phase 2 registeredKelun Phase 1 recruiting; Phase 2 registered, not yet recruiting; Merck Phase 1/2 completed. TOP1 ADC. Ownership/rights not inferred from a completed Merck trial; distinct regional trial statuses retained. |
SHR-A1904HengruiPhase 3 recruitingPhase 3 recruiting. TOP1 ADC; second-line gastric/GEJ trial versus chemotherapy; China sites in registry. JS107JunshiPhase 3 recruitingTwo Phase 3 trials recruiting. MMAE ADC; later-line monotherapy and first-line toripalimab/chemotherapy regimens. BL-M05D1Baili / SystImmunePhase 3 recruiting |
IBI343 / TAK-921Innovent / TakedaChina NDA acceptedChina NDA accepted; positive Phase 3 interim analysis announced 4 Jun 2026. TOP1-payload ADC; later-line gastric filing and Phase 3 pancreatic expansion. Full comparative data remain important. LM-302LaNova / Sino BiopharmaceuticalChina NDA acceptedChina NDA accepted; positive pivotal interim analysis announced 23 Jun 2026. MMAE ADC; both pivotal endpoints reported met; detailed results planned early 2027. Current sponsor replaces historical BMS attribution. AZD0901 / Sone-VeAstraZenecaOS endpoint met; PFS not metPhase 3 positive OS topline; no approval established in reviewed sources. MMAE ADC; 3L+ OS primary and 2L+ OS secondary endpoints met; 2L+ PFS primary not significant. First-line Phase 3 also recruiting. |
— |
| Bispecifics | Givastomig / ABL111NovaBridge / ABL Bio · 4-1BBPhase 2 recruitingRandomized Phase 2 recruiting; Phase 3 planned, not established as started. CLDN18.2 x 4-1BB; first-line immunochemotherapy; low-expression eligibility. Sponsor aims for Phase 3 as early as year-end 2026. Spevatamig / PT886Phanes · CD47Phase 1/2 recruitingPhase 1/2 recruiting. CLDN18.2 x CD47; differentiates through macrophage checkpoint biology. |
ASP2138Astellas · CD3Phase 3 recruitingPhase 3 recruiting; first patient dosed Aug 2026. CLDN18.2 x CD3; subcutaneous administration; first-line pembrolizumab/chemotherapy combination. QLS31905Qilu · CD3Pancreatic Phase 3 recruitingPancreatic Phase 3 recruiting; gastric Phase 3 not yet recruiting. CLDN18.2 x CD3; first-line pancreatic and gastric programs at different stages of trial initiation. |
— | — |
| Cell therapies | TAC01-CLDN18.2TriumviraPhase 1/2 follow-upPhase 1/2 active, not recruiting; last update Feb 2025. T-cell antigen coupler (TAC) product, a different engineered T-cell approach from conventional CAR-T. |
— | — | Satri-cel / CT041CARsgenChina approvedChina approved 22 Jun 2026; HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer after at least two prior lines. Later-line gastric/GEJ approval in China; pancreatic adjuvant expansion remains investigational. |
Selected programs. Phase 3 underway includes active follow-up; registration alone is shown separately. Approval applies only to the market stated. Earlier trial listings can lag current activity.
Map as PDF · 22 reviewed profiles as CSV · 22 reviewed profiles as JSON
The commercial reference points
Zolbetuximab (VYLOY), Astellas, is FDA-approved with chemotherapy for first-line HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer. Satri-cel (CT041), CARsgen, was approved in China on 22 June 2026 after at least two prior lines of therapy in CLDN18.2-positive, HER2-negative advanced gastric/GEJ cancer. Their approved populations and treatment settings differ. FDA approval, CARsgen announcement.
Three ADCs closest to the next commercial wave
- IBI343 / TAK-921 — Innovent / Takeda. China accepted the NDA after a positive interim analysis of G-HOPE-001. The program also has a Phase 3 pancreatic cancer study. Takeda holds rights outside Greater China. Innovent filing announcement, Takeda agreement.
- LM-302 — LaNova / Sino Biopharmaceutical. China NDA acceptance was announced on 23 June 2026. The sponsor reported both pivotal endpoints met and guided detailed results to early 2027. The current developer differs from the historical BMS attribution in the raw export. Sino announcement.
- Sonesitatug vedotin / AZD0901 — AstraZeneca. The Phase 3 trial met its third-line-or-later overall-survival primary endpoint and its second-line-or-later overall-survival secondary endpoint. The progression-free-survival primary endpoint was not statistically significant. This is pivotal survival evidence, not an approval. July 2026 results.
Where the next competition is forming
First-line combinations. Astellas dosed the first patient in ASP2138’s Phase 3 study in August 2026, combining the CLDN18.2 × CD3 bispecific with pembrolizumab and chemotherapy. Givastomig, a CLDN18.2 × 4-1BB bispecific from NovaBridge/ABL Bio, is in randomized Phase 2, with Phase 3 initiation planned as early as year-end 2026. A planned milestone is not a completed one. ASP2138, givastomig update.
Broader biomarker eligibility. SPOTLIGHT required moderate/strong CLDN18.2 staining in at least 75% of tumor cells. AstraZeneca’s pivotal ADC trial used at least 25% at any staining intensity; GIVA-2 allows at least 1% at intensity 1+ or higher. Different assays, thresholds and treatment lines make a simple cross-trial response-rate ranking misleading. SPOTLIGHT, CLARITY-Gastric01, GIVA-2.
Pancreatic cancer. IBI343 and QLS31905 have recruiting Phase 3 trials. FG-M108’s pancreatic Phase 3 is registered but not yet recruiting, while satri-cel is being studied in the adjuvant setting. These are investigational uses. IBI343, QLS31905, FG-M108, satri-cel.
Licensing puts the programs in context
| Agreement | Asset / rights | Disclosed economics |
|---|---|---|
| AstraZeneca / KYM · 2023 | CMG901 / AZD0901 · global | $63m upfront; up to $1.1bn additional milestones, plus royalties |
| Astellas / Evopoint · 2025 | XNW27011 / ASP546C · outside Greater China | $130m upfront; up to $70m near-term payments and $1.34bn additional milestones, plus royalties |
| Takeda / Innovent · 2025 | Portfolio including IBI343 · IBI343 rights outside Greater China | $1.2bn portfolio upfront, including $100m equity; IBI343’s individual allocation was not disclosed |
The strategic pattern is acquisition of access to differentiated clinical programs. The portfolio-level Takeda payment should not be treated as a valuation of IBI343 alone, and contingent milestones are not money already paid.
The full pipeline: preclinical to approval
The shortlist above highlights selected competitors. The full capture contains 185 asset records, including 105 preclinical and 38 Phase 1 records. This bullseye shows every captured ID, with separate Phase 2 and Phase 1 rings. Hover for a quick view, or click or tap a dot to keep its details open.
The chart uses recorded phase with two reviewed updates: satri-cel moves from Phase 2 to approved in China, and SOT102 moves from Phase 2 to discontinued. That produces 2 approved, 12 Phase 3/registered, 22 Phase 2, 38 Phase 1, 105 preclinical and 6 discontinued/historical records. The original export has 24 Phase 2 records; both versions remain available in each record’s details and the full-cohort downloads.
Phase 3 includes registered trials that have not begun recruiting. The cohort also retains overlapping aliases and four records flagged as diagnostic; 185 records does not mean 185 distinct active therapeutic programs. Single-record preclinical and historical developers share a sector to keep labels readable, while every asset retains its own dot and developer details.
All 185 records as CSV · All 185 records as JSON
Reading this snapshot
The selected program map and full-cohort bullseye serve different levels of detail; neither is a count of every active competitor. The raw cohort includes diagnostic assets, overlapping aliases and records marked Stale, a maintenance label that does not establish discontinuation. The 186-trial capture covers ClinicalTrials.gov; additional registries were not pulled for this example.
Two historical programs are retained in the downloads. SOT102 is discontinued despite its raw Active label; the sponsor-authored publication and registry confirm termination. Elevation’s EO-3021 program was discontinued in March 2025, which does not establish the status of every CSPC territory. SOT102 publication, EO-3021 announcement.
The workbook preserves source drug IDs, trial IDs, raw records and a correction log. Regulatory filings, clinical readouts and approvals are kept separate throughout.